News
FIXX
--
0.00%
--
Earnings Preview: Homology Medicines (FIXX) Q4 Earnings Expected to Decline
Zacks.com · 3d ago
DJ Homology Medicines Initiated at Hold by Stifel
Dow Jones · 5d ago
DJ Homology Medicines Price Target Announced at $14.00/Share by Stifel
Dow Jones · 5d ago
The Renaissance Of The Moonshot Era
Investing in Potentially World-Altering Innovation
Benzinga · 5d ago
--Analyst Actions: Stifel Starts Homology Medicines at Hold With $14 Price Target
MT Newswires · 5d ago
Homology Medicines (FIXX) Receives a Buy from Oppenheimer
Oppenheimer analyst Matthew Biegler maintained a Buy rating on Homology Medicines (FIXX) today and set a price target of $27.00. The company's shares
SmarterAnalyst · 6d ago
Homology Medicines Regains Global Rights To Novartis Ophthalmology Program
Homology Medicines Inc (NASDAQ: FIXX) has 
Benzinga · 6d ago
BRIEF-Homology Medicines Regains Worldwide Rights To Ophthalmology Program Based On Its In Vivo Nuclease-Free Gene Editing Platform
reuters.com · 6d ago
Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform
- Company plans to continue advancing ophthalmic program toward a development candidate for lead indication -
GlobeNewswire · 6d ago
RBC Capital Reaffirms Their Buy Rating on Homology Medicines (FIXX)
RBC Capital analyst Luca Issi maintained a Buy rating on Homology Medicines (FIXX) yesterday and set a price target of $30.00. The company's shares closed
SmarterAnalyst · 02/26 01:48
Homology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences
BEDFORD, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today presentations at the following virtual conferences: Cowen 41st Annual Health Care Conference Panel discus...
GlobeNewswire · 02/25 13:00
What Type Of Shareholders Own The Most Number of Homology Medicines, Inc. (NASDAQ:FIXX) Shares?
If you want to know who really controls Homology Medicines, Inc. ( NASDAQ:FIXX ), then you'll have to look at the...
Simply Wall St. · 02/19 07:30
Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome
- IND-Enabling Studies Demonstrated Potential of a Single I.V. Administration of HMI-203 to Address Peripheral and CNS Components of Disease - - Data at WORLDSymposium™ Support Plans to Initiate a HMI-203 Phase 1/2 Clinical Trial This Year - BEDFORD, Mass....
GlobeNewswire · 02/08 19:50
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative
First four investments of new program created to support clinical-stage biotechnology companies New investments include companies focused on Oncology, Rare Disease, and Inflammation & Immunology NEW YORK--(BUSINESS
Benzinga · 01/12 11:50
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative
--New investments include companies focused on Oncology, Rare Disease, and Inflammation & Immunology
BusinessWire · 01/12 08:45
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative
--New investments include companies focused on Oncology, Rare Disease, and Inflammation & Immunology
BusinessWire · 01/12 08:45
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative
--New investments include companies focused on Oncology, Rare Disease, and Inflammation & Immunology
BusinessWire · 01/12 08:45
AY, ABUS, ACLS and FIXX among after-hours movers
Gainers: [[VIVO]] +6%. [[ABUS]] +4.6%. [[AY]] +4.2%. [[EBON]] +3.5%. [[TSE]] +3.4%.Losers: [[ACLS]] -14%. [[DOGZ]] -8.5%. [[HX]] -7.8%. [[FIXX]] -5.9%. [[JRJC]] -2.1%.
Seekingalpha · 01/08 22:43
Homology Medicines unveils plans to start three gene therapy programs this year
Homology Medicines ([[FIXX]] +4.3%) has outlined plans to initiate two additional Phase 1/2 dose-escalation trials in 2021 with its gene therapy candidate for Hunter syndrome and gene editing candidate, which is
Seekingalpha · 01/06 16:22
Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)
- Clinical Data from pheNIX Gene Therapy Phase 2 Dose Expansion Trial Expected by End of Year; Trial Currently Recruiting Patients -
GlobeNewswire · 01/06 13:00
Webull provides a variety of real-time FIXX stock news. You can receive the latest news about Homology Medicines through multiple platforms. This information may help you make smarter investment decisions.
About FIXX
Homology Medicines, Inc. is a genetic medicines company translating gene editing and gene therapy technology into treatments for patients with rare diseases. The Company is focused on developing a pipeline of new medicines that address and cure the underlying cause of monogenic diseases in the liver, central nervous system (CNS), bone marrow, lung and the eye. The Company’s lead product candidate, HMI-102 is a gene therapy for the treatment of phenylketonuria (PKU). Its PKU program is focused on adults using the gene therapy approach. The Company’s suite of 15 adeno-associated virus vectors (AAVHSCs) enables it to focus on a method of gene editing called gene correction. The Company’s diverse set of AAVHSCs allows it to precisely target, via a single intravenous injection, a wide range of disease-relevant tissues, including the liver, central nervous system, or CNS, bone marrow, lung, muscle and eye, across both modalities - gene editing and gene therapy.